Red Nucleus, a life sciences services company, has acquired Bridge Medical Consulting, a health economics and outcomes research consultancy. Red Nucleus has been majority owned by THL since 2024 and is expanding its value and evidence platform through add-on acquisitions.
Founded in 2011 by Paul Gandhi, Bridge Medical Consulting provides evidence synthesis, integrated evidence planning, health economic modeling, statistics, and real-world evidence used by pharmaceutical and biotechnology customers to support regulatory, reimbursement, and market access decisions. Paul Gandhi serves as chief executive officer. The company is headquartered in London. Bridge Medical Consulting serves customers across Europe and the United States.
Philadelphia-are-based Red Nucleus provides learning and development services, including training programs designed for pharmaceutical sales teams, clinical staff, and healthcare professionals.
THL was founded in 1974 and is one of the oldest private equity investment firms in the United States. Industries of interest include financial services, healthcare, and technology & business solutions. Since its founding, Boston-based THL has raised over $35 billion of equity capital, acquired over 170 portfolio companies, and completed over 600 add-on acquisitions. THL’s investment in Red Nucleus was through its ninth fund which closed in October 2021 with $5.6 billion in committed capital.
